Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?
Having lost market share in recent years to HIV regimens containing ViiV's Tivicay, will a showing of non-inferiority across four head-to-head Phase III studies give bictegravir the market edge Gilead seeks?
You may also be interested in...
Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's future growth is unclear, however, without M&A.
The latest HIV drug development news and highlights from our FDA Performance Tracker.
The battle of the HIV giants ViiV Healthcare and Gilead Sciences continues with the first filing for a two-drug regimen for use against HIV infection in the US and EU.